Accéder au contenu
Merck

Different glycosylation profiles of cystatin F alter the cytotoxic potential of natural killer cells.

Cellular and molecular life sciences : CMLS (2023-12-14)
Emanuela Senjor, Martina Pirro, Urban Švajger, Mateja Prunk, Jerica Sabotič, Anahid Jewett, Paul J Hensbergen, Milica Perišić Nanut, Janko Kos
RÉSUMÉ

Cystatin F, a cysteine peptidase inhibitor, is a potent modulator of NK cytotoxicity. By inhibiting granule-mediated cytotoxicity pathway, cystatin F induces formation of non-functional NK cell stage, called split-anergy. We show that N-glycosylation determines the localization and cellular function of cystatin F. Cystatin F mostly exhibited high-mannose glycosylation in U-937 cells, both high-mannose and complex glycosylation in NK-92 and primary NKs, and predominantly complex glycosylation in super-charged NKs. Manipulating N-glycosylation with kifunensine increased high-mannose glycosylation of cystatin F and lysosome localisation, which decreased cathepsin C activity and reduced NK cytotoxicity. Mannose-6-phosphate could significantly reduce the internalization of extracellular cystatin F. By comparing NK cells with different cytotoxic potentials, we found that high-mannose cystatin F was strongly associated with lysosomes and cathepsin C in NK-92 cell line. In contrast, in highly cytotoxic super-charged NKs, cystatin F with complex glycosylation was associated with the secretory pathway and less prone to inhibit cathepsin C. Modulating glycosylation to alter cystatin F localisation could increase the cytotoxicity of NK cells, thereby enhancing their therapeutic potential for treating cancer patients.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
7-AAD Ready Made Solution, 1 mg/mL
Sigma-Aldrich
Anti-TGN46 antibody, Mouse monoclonal, clone TGN46-8, purified from hybridoma cell culture
Sigma-Aldrich
Anti-CST7 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution